Clinical Research Directory
Browse clinical research sites, groups, and studies.
Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Summary
This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study. The primary objective is to evaluate the safety of UTAA91 injection in treating subjects with relapsed/refractory autoimmune inflammatory diseases (AID).
Official title: A Single-Arm, Open-Label, Single-Center Investigator-Initiated Early-Stage Clinical Study for Relapsed/Refractory (R/R) Autoimmune Diseases
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2025-05-18
Completion Date
2027-04-30
Last Updated
2025-05-14
Healthy Volunteers
No
Conditions
Interventions
UTAA91 injection
Infusion of UTAA91 injection in subjects screened after signing informed consent.
Locations (1)
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China